Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Investigation of Therapeutic Efficacy and Safety of UMSCs for the Management of Retinitis Pigmentosa (RP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04763369
Recruitment Status : Recruiting
First Posted : February 21, 2021
Last Update Posted : February 21, 2021
Sponsor:
Collaborators:
The Layton Rahmatullah Benevolent Trust (LRBT) Free Eye Hospital, Township Lahore.
Centre of Excellence in Molecular Biology (CEMB), University of the Punjab, Lahore.
Information provided by (Responsible Party):
Prof. Dr. Sheikh Riazuddin, Jinnah Burn and Reconstructive Surgery Centre, Lahore

Brief Summary:
Retinitis pigmentosa (RP) is the most common hereditary retinal disorder (accounts for 20% of children attending blind schools in Pakistan) which causes degeneration of rod and cone photoreceptors. Rods and cones largely depend on the retinal pigment epithelium for their proper functioning. Various growth factors and their receptors are present in retinal epithelium and a number of genes are responsible for the production of these growth factors. Genetic mutation in any of these genes causes retinal degeneration by progressive loss of retinal pigment epithelium and photoreceptors. The disease initially starts with night blindness and leads to the loss of central vision and eventually total blindness. To date, there is no definitive cure for patients suffering from RP. Recently, stem cell based therapies have shown great promise for the management of RP. It is well documented that umbilical cord derived mesenchymal stem cells (UMSCs) have the ability to release various paracrine and immunomodulatory factors that are similar to those synthesized by retinal pigment epithelium. Multiple routes including systemic (intravenous) and localized (subretinal, intravitreal, suprachoroidal and sub-tenon) have been employed to administer UMSCs for the management of RP. It is important to note that deep sub-tenon region (space between the sclera and the conjunctiva) acts as both natural culture medium for cells and as immune privileged site because of avascularity of the region. It has been reported that the injection of UMSCs in sub-tenon space of human subjects have improved the visual acuity even after 1 year post-injection. In addition, the injection of UMSCs in suprachoroidal space enhances the entry of growth factors released by the cells into choroidal flow and maintain the constant growth factors secretion to the choroidal and retinal tissues. Limoli and colleagues were the first to report the suprachoroidal administration of cells being the safe mode of cell delivery with no complications. The present study is aimed to investigate the safety and therapeutic efficacy of UMSC injection employing two different routes (sub-tenon injection versus suprachoroidal injection) for the treatment of RP in human subjects.

Condition or disease Intervention/treatment Phase
Retinitis Pigmentosa (RP) Biological: Injection of stem cells in sub-tenon space of eye for the management of retinitis pigmentosa Biological: Injection of stem cells in suprachoroidal space of eye for the management of Retinitis Pigmentosa Phase 2

Detailed Description:
Isolation and characterization of human umbilical cord derived mesenchymal stem cells (UMSCs): The culturing and characterization of UMSCs will be performed as documented by Ali and colleagues. Briefly, human umbilical cord tissues along with informed consent forms will be collected from COVID-19- and hepatitis B, C virus-negative women with healthy pregnancies during the Cesarean Section surgery after completion of gestation period. The umbilical cord tissue will be transported in sterile 1x phosphate-buffered saline (PBS) containing penicillin and streptomycin on ice. In the biosafety cabinet, the cord will be washed with 4-5 changes of sterile 1x PBS and placed in a Petri plate with 15ml PBS. The cord will then gently scrap with a surgical blade to remove any dead cells. A 9 cm umbilical cord will be cut into three equal pieces and wash thoroughly to remove blood clots, umbilical cord arteries, and veins. Segments will be washed three times with PBS and minced. The minced pieces will be incubated in 17.5ml of collagenase solution (201 U/ml collagenase type I in serum-free DMEM-HG) in a 50ml conical tube for ~3 hrs in an incubator at 5% CO2, 95% humidity at 37oC. After ~3 hrs, the digested lysate will be passed through strainer and will be diluted three times with 1x PBS. Following centrifugation, the cells will be seeded into two T-25cm2 flasks and will be placed in an incubator at 5% CO2, 95% humidity at 37o C. The flasks will be fed with fresh media (DMEM-HG supplemented with 20% FBS and 1% antibiotic solution) every third day. At around day 18, cells will reach up to 85% confluency and will be transferred in two T-75cm2 flasks with media replaced at alternate days. UMSCs at P3 will be characterized using different specific antibodies. Cells at P3 will be employed for injection in RP patients.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

Group 1: Five (5) subjects will be treated by injecting UMSCs in sub-tenon space of eye.

Group 2: Five (5) subjects will be treated by suprachoroidal injection of UMSCs .

From two subjects in group 1 & 2 will not be treated 24 hrs apart. Patients will be randomized in a 1:1 ratio (Sub-tenon injection of UMSCs : Suprachoroidal injection of UMSCs).

Note: In total, twenty five patients will be subjected to cell injection for each of group 1 & 2.

Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Investigation of Therapeutic Efficacy and Safety of Umbilical Cord Derived Mesenchymal Stem Cells (UMSCs) for the Management of Retinitis Pigmentosa (RP)
Estimated Study Start Date : February 2021
Estimated Primary Completion Date : May 2022
Estimated Study Completion Date : June 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Sub-tenon injection group
In total twenty five subjects will be treated by injecting UMSCs in sub-tenon space of eye.
Biological: Injection of stem cells in sub-tenon space of eye for the management of retinitis pigmentosa
Cultured stem cells will be injected in the sub-tenon space of eye and patients will be monitored and evaluated for outer retinal thickness, early treatment of diabetic retinopathy study visual acuity, visual field sensitivity, fundus photography, amplitudes of multifocal electroretinogram and implicit times of multifocal electroretinogram at baseline (day 0) and days 30, 60, 90, 180, 270 and 360.

Experimental: Suprachoroidal injection group
A total of twenty five subjects will be treated by suprachoroidal injection of UMSCs.
Biological: Injection of stem cells in suprachoroidal space of eye for the management of Retinitis Pigmentosa
Cultured stem cells will be injected in the suprachoroidal space of eye and patients will be monitored and evaluated for outer retinal thickness, early treatment of diabetic retinopathy study visual acuity, visual field sensitivity, fundus photography, amplitudes of multifocal electroretinogram and implicit times of multifocal electroretinogram at baseline (day 0) and days 30, 60, 90, 180, 270 and 360.




Primary Outcome Measures :
  1. Evaluation of safety related adverse ocular events including immune response [ Time Frame: Baseline to day 360 ]
    No significant side effects in stem cell treated subjects

  2. Ophthalmic examination for best-corrected visual acuity (BCVA) using early treatment of diabetic retinopathy study (ETDRS) chart [ Time Frame: Baseline to day 360 ]
    Change in best corrected visual acuity (BCVA)


Secondary Outcome Measures :
  1. Measurement of electrical activity/function of retina using Electroretinography (ERG) test [ Time Frame: Baseline to day 360 ]
    Change in electrical response/function of various cell types of retina

  2. Evaluation of outer retinal thickness using Optical Coherence Tomography (OCT) imaging test [ Time Frame: Baseline to day 360 ]
    Alteration in retinal thickness

  3. Examination of retinal damage by Fundus Photography [ Time Frame: Baseline to day 360 ]
    Change in retinal Fundus image

  4. Evaluation of visual field sensitivity using perimeter [ Time Frame: Baseline to day 360 ]
    Change in visual field sensitivity



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients who will be voluntarily participated for UMSCs injection for the treatment of RP.
  • Patients who will be able to adhere to the study follow-up and protocol requirements.
  • Individuals with age ranges from 18 years to 70 years will be included.
  • Patients with best corrected visual acuity (BCVA) from 50 letters to 110 letters or <20/50 in the ETDRS chart testing (Topcon CC-100 XP, Japan).
  • Mean deviation values ranging between -33.0 and - 5.0 dB with compass visual field analysis (threshold 24-2, Sita Standard, Stimulus 3-white).
  • Diagnosis of any phenotypic or genotypic variation of RP, confirmed by clinical history, fundus appearance, visual field, electroretinogram and genetic mutation analysis.

Exclusion Criteria:

  • Presence of cataracts or other media opacity that might affect the visual field, mean deviation, or electroretinogram recordings.
  • Presence of another ocular disease except RP (i.e., uveitis, strabismus, glaucoma) that causes visual field and optic disc changes.
  • Presence of any systemic disorder that may affect visual functions. This includes diabetes, neurological disorders, and uncontrolled systemic hypertension.
  • Smokers will be excluded from the study.
  • Individuals who underwent ocular surgery except cataract extraction will be considered as excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04763369


Contacts
Layout table for location contacts
Contact: Sheikh Riazuddin, PhD +9242935164422 riazuddin@aimrc.org
Contact: Muhammad Ali, PhD +923218429448 riazuddin@aimrc.org

Locations
Layout table for location information
Pakistan
Stem Cell laboratory, Jinnah Burn & Reconstructive Surgery Centre Recruiting
Lahore, Punjab, Pakistan, 54550
Contact: Muhammad Ali, PhD    +923218429448    riazuddin@aimrc.org   
Sponsors and Collaborators
Jinnah Burn and Reconstructive Surgery Centre, Lahore
The Layton Rahmatullah Benevolent Trust (LRBT) Free Eye Hospital, Township Lahore.
Centre of Excellence in Molecular Biology (CEMB), University of the Punjab, Lahore.
Investigators
Layout table for investigator information
Principal Investigator: Sheikh Riazuddin, PhD Jinnah Burn & Reconstructive Surgery Center, Lahore
Principal Investigator: Zaheer-ud-Din A Qazi, consultant The Layton Rahmatullah Benevolent Trust (LRBT)
Publications:
Ali M, Mehmood A, Tarar MN, Nawaz Z, Riazuddin SA, Khan A, Riazuddin S. Efficacy of intravenous infusions of UC-derived MSCs for the treatment of COVID-19: A structured summary of a phase II double blinded, randomized controlled clinical trial. Preprint from Research Square, 28 Oct 2020. DOI: 10.21203/rs.3.rs-92995/v2

Layout table for additonal information
Responsible Party: Prof. Dr. Sheikh Riazuddin, Distinguished National Professor, Jinnah Burn and Reconstructive Surgery Centre, Lahore
ClinicalTrials.gov Identifier: NCT04763369    
Other Study ID Numbers: JB&RSC-02
First Posted: February 21, 2021    Key Record Dates
Last Update Posted: February 21, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Prof. Dr. Sheikh Riazuddin, Jinnah Burn and Reconstructive Surgery Centre, Lahore:
Retinitis pigmentosa
Stem cells treatment
Additional relevant MeSH terms:
Layout table for MeSH terms
Retinitis
Retinitis Pigmentosa
Retinal Diseases
Eye Diseases
Eye Diseases, Hereditary
Retinal Dystrophies
Retinal Degeneration
Genetic Diseases, Inborn